Efficacy of Paricalcitol in the Treatment of Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients

被引：0
|
作者：
Ou, Santao [1 ]
机构：
[1] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PUB129
引用
收藏
页码：920 / 920
页数：1
相关论文
共 50 条
  • [31] Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients on Sevelamer Hydrochloride: Which Dialysate Calcium Concentration to Use?
    Sonikian, Macroui
    Metaxaki, Polyxeni
    Karatzas, Ioannis
    Vlassopoulos, Dimosthenis
    BLOOD PURIFICATION, 2009, 27 (02) : 182 - 186
  • [32] Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover study
    Mittman, N.
    Khanna, R.
    Rani, S.
    Chattopadhyay, J.
    Avram, M. M.
    KIDNEY INTERNATIONAL, 2006, 70 : S64 - S67
  • [33] Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: The role of paricalcitol
    Cozzolino, Mario
    Galassi, Andrea
    Gallieni, Maurizio
    Brancaccio, Diego
    CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (02) : 148 - 153
  • [34] Comparison of vitamin D analogues doxercalciferol and paricalcitol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Ghorbani, A
    Kostopoulos, K
    Raja, R
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A26 - A26
  • [35] The Impact of Paricalcitol on Parathyroid Gland Size of Secondary Hyperparathyroidism Patients with Long-Term Maintenance Hemodialysis: An Observational Study
    Tao, Chenghui
    Liao, Xiaohui
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 210 - 210
  • [36] Effect of Hybrid Blood Purification Treatment on Secondary Hyperparathyroidism for Maintenance Hemodialysis Patients
    Gao, Xiao-Fang
    Li, Jian-Dong
    Guo, Li
    Guo, Shan-Shan
    Zhang, Ran
    Gou, Yan-Li
    Chen, Hang
    BLOOD PURIFICATION, 2018, 46 (01) : 19 - 26
  • [37] Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
    Sprague, SM
    Llach, F
    Amdahl, M
    Taccetta, C
    Batlle, D
    KIDNEY INTERNATIONAL, 2003, 63 (04) : 1483 - 1490
  • [38] Treatment of secondary hyperparathyroidism with paricalcitol in patients on hemodialysis. Combination with calcimimetics. 2-year experience
    Belechri, Anna Maria
    Giamalis, Panagiotis
    Chatzikyrkou, Christos
    Pateinakis, Papagiotis
    Papagianni, Aikaterini
    Vainas, Andreas
    Dimitriadis, Chrisostomos
    Tsamelasvili, Mzia
    Memmos, Dimitrios
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 358 - 359
  • [39] Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects
    Yan, Yucheng
    Qian, Jiaqi
    Chen, Nan
    Huang, Zhaoxing
    Jiang, Gengru
    Li, Xuewang
    Lin, Hongli
    Liu, Liqiu
    Wang, Mei
    Xing, Changying
    Yu, Xueqing
    Zuo, Li
    Amdahl, Michael
    Khan, Samina
    CLINICAL NEPHROLOGY, 2014, 81 (01) : 20 - 29
  • [40] Biochemical advantages of paricalcitol therapy for secondary hyperparathyroidism (SHPT) in patients (PTS) on maintenance hemodialysis (HD) previously treated with calcitriol.
    Mittman, N
    Khanna, R
    Rani, S
    Avram, MM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A39 - A39
12345